Portfolio of Cancer Immunotherapy Stocks
Here are 18 cancer immunotherapy stocks.
| 18 Cancer+Immunotherapy+Stocks | ||
|---|---|---|
Name | Symbol | Recent Prices |
| Amgen | AMGN | |
| AstraZeneca | AZN | |
| BeiGene Ltd. | BGNE | |
| Bellicum Pharmaceuticals | BLCM | |
| bluebird bio | BLUE | |
| Bristol-Myers Squibb | BMY | |
| Celldex Therapeutics | CLDX | |
| Cellectis | CLLS | |
| Celyad | CYAD | |
| Clovis Oncology | CLVS | |
| Compugen Ltd. | CGEN | |
| Curis | CRIS | |
| CytomX Therapeutics | CTMX | |
| Gilead Sciences | GILD | |
| Incyte Corporation | INCY | |
| Merck | MRK | |
| Nektar Therapeutics | NKTR | |
| Novartis | NVS | |
| Sparkline weekly price charts based on Alpha Vantage data. | ||
Portfolio Values
To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.All 18 stocks are included in the portfolio computations. The current value of the portfolio assumes that $555.56 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.The current value of the $10,000 investment is $8,542. The percent return is -14.58%. The annualized return is -3.10%.
Related Portfolios
Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks